Development of montelukast, a leukotriene antagonist therapy for asthma and allergies
Dr Evans, a proud NZ ex-Pat living in the US will discuss the discovery and biochemistry of leukotrienes and the development of the cysteinyl leukotriene receptor antagonist SingulairTM (montelukast).
She will outline the drug discovery process from understanding leukotriene effects on asthma and allergies, identifying and cloning targets within the leukotriene pathway and the long process to develop an effective, safe therapy that is not a me-too drug.
Dr Evans’s team cloned the CysLT1 receptor after Singulair was launched. The receptor was identified on human lung smooth muscle and inflammatory cells. Montelukast came off patent in 2012 and the generic form was approved by Pharmac in 2018 for New Zealanders suffering from asthma and allergies.
|Date||Tuesday, 12 March 2019|
|Time||12:00pm - 1:00pm|
|Event Category||Health Sciences|
|Location||Biochemistry Seminar Room 231|